Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
37 hedge funds and large institutions have $47.3M invested in Bellerophon Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 0 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
95% more funds holding
Funds holding: 19 → 37 (+18)
65% more capital invested
Capital invested by funds: $28.7M → $47.3M (+$18.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMVA
New Mountain Vantage Advisers
New York
|
+$12.7M |
| 2 |
PCM
Puissance Capital Management
New York
|
+$8.4M |
| 3 |
BlackRock
New York
|
+$3.99M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.93M |
| 5 |
Renaissance Technologies
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Pennant Investors
Summit,
New Jersey
|
-$769K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$261K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$210K |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
-$35K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
BLPH Hedge Fund Activity: Q2 2020 in Review
37 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2020, worth a combined $47.3M — up 65% from $28.7M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BLPH positions and 5 closed out — a net gain of 18 holders — while 11 added to existing stakes and 0 trimmed.
The largest buyer was New Mountain Vantage Advisers, adding an estimated $12.7M. The largest seller was Pennant Investors, exiting entirely with an estimated $769K sold.
- 37 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2020, up from 19 in Q1 2020.
- Funds reported $47.3M of Bellerophon Therapeutics, Inc. stock for Q2 2020, up 65% quarter-over-quarter.
- 23 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2020 and 5 closed out, a net change of +18 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2020 was New Mountain Vantage Advisers, an estimated $12.7M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2020 was Pennant Investors, an estimated $769K sold.
Based on aggregated 13F filings for Q2 2020.